CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · IEX Real-Time Price · USD
0.219
+0.010 (4.78%)
At close: Apr 26, 2024, 12:39 PM
0.218
-0.001 (-0.46%)
After-hours: Apr 26, 2024, 4:00 PM EDT
Company Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors.
The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.
It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D.
Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.
CNS Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 8, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | John Michael Climaco Esq., J.D. |
Contact Details
Address: 2100 West Loop South, Suite 900 Houston, Texas 77027 United States | |
| Phone | 1-800-946-9185 |
| Website | cnspharma.com |
Stock Details
| Ticker Symbol | CNSP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001729427 |
| CUSIP Number | 18978H102 |
| ISIN Number | US18978H2013 |
| Employer ID | 82-2318545 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John Michael Climaco Esq., J.D. | Chief Executive Officer, President and Director |
| Christopher S. Downs C.P.A., CTP, FP&A | Chief Financial Officer |
| Dr. Sandra L. Silberman M.D., Ph.D. | Chief Medical Officer |
| Dr. Waldemar Priebe Ph.D. | Founder |
| Dr. Donald H. Picker Ph.D. | Chief Science Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | 8-K | Current Report |
| Apr 10, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | PRE 14A | Other preliminary proxy statements |
| Feb 27, 2024 | 8-K | Current Report |
| Feb 21, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 2, 2024 | 8-K | Current Report |
| Jan 31, 2024 | 424B4 | Prospectus |